AOD9604 5mg

What is AOD 9604?

AOD9604 is a synthetic peptide fragment derived from human growth hormone (hGH). Specifically, it is based on the C-terminal fragment of hGH (residues 177–191). This peptide was originally developed as a potential therapeutic agent for obesity and metabolic disorders. Unlike full-length hGH, AOD9604 retains the lipolytic (fat-reducing) activity without influencing growth, which has made it a candidate for weight management therapies. The purpose of this research description is to examine AOD9604’s structure, mechanism of action, therapeutic potential, and the evidence supporting its clinical use.

Structural Basis

The sequence of AOD9604 corresponds to the amino acid residues 177–191 of the human growth hormone. This short peptide was found to maintain the fat-burning properties of the full-length hormone while lacking the proliferative effects associated with hGH, such as increases in insulin-like growth factor 1 (IGF-1) levels that drive growth and muscle anabolism. The selective retention of the lipolytic activity has made AOD9604 an interesting molecule for the treatment of obesity and related conditions.

Mechanism of Action

AOD9604 has been reported to stimulate lipolysis, the breakdown of fats into free fatty acids and glycerol, while inhibiting lipogenesis, the metabolic process by which fat is formed. The peptide binds to receptors on adipose tissue and activates pathways associated with fat metabolism, without affecting glucose metabolism or inducing growth effects. Studies have suggested that AOD9604 may act through the beta-3 adrenergic receptor, which is known to regulate energy expenditure and fat oxidation.

In animal models, AOD9604 demonstrated significant effects on fat reduction without altering glucose homeostasis or inducing undesired growth-related side effects. These findings suggest that AOD9604 may offer a safer alternative to traditional hGH therapies for obesity by avoiding the anabolic effects that hGH elicits through IGF-1 stimulation.

Therapeutic Potential and Clinical Studies

AOD9604 has been investigated for its potential to treat obesity, metabolic disorders, and other conditions related to excessive fat accumulation. Several preclinical and early-stage human studies have been conducted to evaluate its safety and efficacy.

Animal Studies: In rodent models, AOD9604 was shown to reduce body fat mass, particularly in visceral fat, without affecting overall body weight or inducing hypoglycemia. These studies provided preliminary evidence of the peptide’s fat-burning capacity and paved the way for further investigation in human subjects (Ng et al., 2000).

Human Clinical Trials: Early clinical trials in humans have suggested that AOD9604 is well-tolerated, with no major adverse events reported. A phase IIb study conducted in obese individuals showed modest reductions in body fat, although the outcomes were not as significant as initially expected (Dean, 2011). Importantly, AOD9604 did not alter IGF-1 levels, indicating that it lacks the proliferative properties of hGH.

Conclusion

AOD9604 is a promising peptide derived from human growth hormone, offering selective fat-reducing effects without the growth-promoting side effects associated with hGH. Early animal studies and limited human trials have indicated its potential as a treatment for obesity and related metabolic disorders. However, further research, particularly large-scale clinical trials, is needed to establish its long-term safety and efficacy. Until then, AOD9604 remains an experimental compound with therapeutic promise.

References

• Ng, F. M., Anderson, P. J., & Siegling, A. (2000). The use of human growth hormone fragment AOD9604 in the treatment of obesity. International Journal of Obesity, 24(10), 1447-1457.
• Dean, H. (2011). AOD9604 for obesity: Investigating the clinical potential. Journal of Obesity and Weight Loss Therapy, 1(1), 5-12.

AOD9604 Technical Specifications